Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass. , March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2024 and provided a corporate update.» Mehr auf prnewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Pulmatrix, Inc. (NASDAQ:PULM)'s merger with Cullgen Inc. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. If you are a Pulmatrix shareholder, click here to learn more about your rights and options.» Mehr auf accesswire.com
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix, Inc. (NasdaqCM: PULM) and Cullgen Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whethe.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 2,88k | 99,86% |
Bruttoeinkommen | 2,88k | 99,84% |
Nettoeinkommen | −1,91 Mio | 1,29% |
EBITDA | −1,88 Mio | 10,60% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 19,84 Mio€ |
Anzahl Aktien | 3,65 Mio |
52 Wochen-Hoch/Tief | 9,48€ - 1,57€ |
Dividenden | Nein |
Beta | 1,55 |
KGV (PE Ratio) | −2,28 |
KGWV (PEG Ratio) | −2,00 |
KBV (PB Ratio) | 2,43 |
KUV (PS Ratio) | 2,79 |
Unternehmensprofil
Name | Pulmatrix |
CEO | Peter Ludlum CMA, MBA |
Website | |
Mitarbeiter | 2 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | PULM |
Assets entdecken
Shareholder von Pulmatrix investieren auch in folgende Assets